JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 20 June 2005. doi:10.1083/jcb1696iti5
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 169, Number 6, 835-835
This Article
Right arrow Full Text (PDF, 613K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In This Issue

Tumors feed on collagen



Collagen (brown) accumulation around tumor cells is higher in mice lacking uPARAP (right).

Curino et al. (page 977) find that the ability of tumor support cells to take in and degrade collagen helps tumor growth. Blocking the collagen uptake receptor, they show, keeps murine breast tumors in check.

Collagen, the major component of the extracellular matrix, can be degraded extracellularly by proteases or intracellularly in lysosomes. Mice lacking uPARAP, which mediates the uptake of collagen and thus the intracellular pathway, develop normally. The authors now show that these mice have an advantage over the wild type when it comes to controlling cancer progression.

Stromal cells surrounding breast tumors in the mutant mice did not take in and degrade collagen efficiently. Tumor growth was subsequently restricted in these mice. Proliferation and apoptosis rates of the tumor cells were unchanged, however, so the signals affected by collagen degradation that lead to tumor growth are still unclear.

Blocking the extracellular pathway is also known to limit tumor growth in mice, but this requires the inhibition of many proteases. The intracellular pathway, by contrast, can be blocked by disrupting only uPARAP. This strategy might be useful for the treatment of human cancers and other disorders involving the degradation of connective tissues, such as arthritis, which are all associated with strong intracellular collagen turnover. {iti_end}



Nicole LeBrasseur

lebrasn{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy
Alejandro C. Curino, Lars H. Engelholm, Susan S. Yamada, Kenn Holmbeck, Leif R. Lund, Alfredo A. Molinolo, Niels Behrendt, Boye Schnack Nielsen, and Thomas H. Bugge
J. Cell Biol. 2005 169: 977-985. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF, 613K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents